Previous Article
We need faster endpoints for targeted cancer drugs, and there is one
We need faster endpoints for targeted cancer drugs, and there is one

As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how t...

Next Article
The impact of COVID-19 on clinical trials in rare disease and oncology
The impact of COVID-19 on clinical trials in rare disease and oncology